Viridian Therapeutics, Inc./DE Income Tax Expense
Viridian Therapeutics, Inc./DE (VRDN) reported Income Tax Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-02-26
- Viridian Therapeutics, Inc./DE income tax expense (benefit) for fiscal 2025 was $0.00.
- Viridian Therapeutics, Inc./DE income tax expense (benefit) for fiscal 2015 was $0.00.
- Viridian Therapeutics, Inc./DE income tax expense (benefit) for fiscal 2014 was $0.00.
| Period end | Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2015-12-31 | $0.00 10-K · filed 2016-03-21 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |